A Phase 1 Open-label Trial to Evaluate the Pharmacokinetics and Safety Following Single Dose of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
Latest Information Update: 01 Jun 2023
At a glance
- Drugs Tavapadon (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Cerevel Therapeutics
- 26 May 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2022 New trial record